(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of -67.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Keros Therapeutics's revenue in 2025 is $246,718,000.On average, 13 Wall Street analysts forecast KROS's revenue for 2025 to be $7,545,226,649, with the lowest KROS revenue forecast at $6,568,484,476, and the highest KROS revenue forecast at $8,114,942,139. On average, 13 Wall Street analysts forecast KROS's revenue for 2026 to be $244,216,009, with the lowest KROS revenue forecast at $0, and the highest KROS revenue forecast at $1,439,521,760.
In 2027, KROS is forecast to generate $256,067,310 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,279,574,898.